Article

Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53

2025-04-13

Abstract excerpt

TP53-mutant acute myeloid leukemia (AML) is associated with particularly poor clinical outcomes and resistance to current therapies. While immunotherapy has revolutionized treatment for other hematologic malignancies, its efficacy in TP53-mutant AML remains limited. Although TP53 mutations in leukemic blasts are well characterized, their presence and functional consequences in immune cells have not been fully expl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b8140e14-55f3-55c8-aa07-8efef8a34feb
DOI: 10.1101/2025.04.11.25325281

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53DOI 10.1101/2025.04.11.25325281Read

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.Semantic proximity Read

Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.Semantic proximity Read

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.Semantic proximity Read

Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemiaSemantic proximity Read

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read

The role of TP53 in acute myeloid leukemia: Challenges and opportunitiesSemantic proximity Read

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read

<i>TP53</i> abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemiaSemantic proximity Read

Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia.Semantic proximity Read

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic ImplicationsSemantic proximity Read

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.Semantic proximity Read